New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For JNJ;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
16:49 EDTJNJJ&J says Costco filed complaint against Vision Care unit
Subscribe for More Information
07:43 EDTJNJExpensive drugs drove over 25% of 2013 Medicare drug spending, WSJ says
Subscribe for More Information
April 30, 2015
07:59 EDTVRTXVertex price target raised to $150 from $131 at Leerink
Subscribe for More Information
April 29, 2015
17:49 EDTVRTXVertex CEO says Orkambi currently under review by the FDA
Subscribe for More Information
17:00 EDTJNJJohnson & Johnson announces further patent action related to Remicade
Subscribe for More Information
16:04 EDTVRTXVertex sees FY15 Kalydeco revenue $560M-$580M
Sees FY15 combined non-GAAP R&D and SG&A expenses will be in the range of $1.05B-$1.10B.
16:02 EDTVRTXVertex reports Q1 EPS (62c), consensus (75c)
Reports Q1 revenue $138.51M, consensus $142.38M.
15:00 EDTVRTXNotable companies reporting after market close
Subscribe for More Information
12:25 EDTJNJPerrigo rumored to possibly draw interest beyond Mylan bid, Bloomberg says
Subscribe for More Information
April 27, 2015
06:19 EDTJNJPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
14:20 EDTJNJEarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
11:02 EDTJNJJohnson & Johnson increases dividend by 7.1% to 75c
Subscribe for More Information
10:02 EDTJNJAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
April 21, 2015
13:34 EDTVRTXGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
12:33 EDTVRTXOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTVRTXVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
08:14 EDTVRTXGilead should buy Vertex, says Bernstein
Subscribe for More Information
April 20, 2015
14:32 EDTJNJPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
06:59 EDTJNJJohnson & Johnson added to short-term buy list at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use